(Reuters) -MeiraGTx Holdings has signed a deal with Eli Lilly, potentially worth over $475 million, granting the pharma giant ...

Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...

Eli Lilly has penned a research pact worth $1.2 billion in biobucks with SanegeneBio to help pinpoint cardiometabolic RNAi ...

Eli Lilly shares are rising Monday after Leerink Partners upgraded the stock to Outperform and raised its price target to ...

MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...

Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...

Eli Lilly's next generation of weight loss drugs appear to show promise, possibly leading to even faster weight loss and ...

For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades.

The Trump administration on Thursday rolled out a much-anticipated deal with drugmakers Eli Lilly and Novo Nordisk that aims ...

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...

The White House is nearing an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some of their ...

In the preceding three months, 12 analysts have released ratings for Eli Lilly (NYSE: LLY ), presenting a wide array of perspectives from bullish to bearish. The following table summarizes their ...